8月13日亨利医药(KBP)在官网发布声明回应新加坡国际商事法庭(SICC)作出的进一步裁定。该裁定决定维持对KBP及其

智通财经
Aug 13
8月13日亨利医药(KBP)在官网发布声明回应新加坡国际商事法庭(SICC)作出的进一步裁定。该裁定决定维持对KBP及其创始人黄振华的临时禁令以支持KBP与诺和诺德(Novo Nordisk A/S)各自启动的仲裁程序。该声明称KBP已先于诺和诺德启动仲裁程序。在SICC作出判决后诺和诺德所申请禁令的有效性将会在仲裁程序中予以判定。前述判决中SICC审查了争议核心的一系列问题包括临床试验的开展及尽职调查的充分性。SICC的结论将由仲裁庭进一步审查。黄振华在此次声明中表示KBP认为诺和诺德终止开发Ocedurenone是错误的因为该药有望惠及患者。KBP将向仲裁庭证明这一点。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10